Pharmacological evaluation of morphine and non-opioid analgesic adjuvants in a mouse model of skin cancer pain.

Abstract

Using a mouse model of advanced skin cancer which has mixed nociceptive-neuropathic pain, we evaluated the analgesic effects of morphine and analgesic adjuvants. Morphine hydrochloride (10--30 mg/kg, oral) and mexiletine hydrochloride (10--30 mg/kg, intraperitoneal) dose-dependently inhibited thermal hyperalgesia. Baclofen (10 mg/kg, subcutaneous) suppressed thermal hyperalgesia, without effects at lower doses of 1 and 5 mg/kg. Ketamine hydrochloride (50 mg/kg, oral) was without effect. Analgesic tolerance was observed after 6th administration of morphine, and it was not developed until at least 7th administration of mexiletine and baclofen. This mouse model of skin cancer may be useful for the pharmacological evaluation of the effects of opioids and analgesic adjuvants on mixed nociceptive-neuropathic pain of advanced cancer.

• Authors: Tsugunobu Andoh, Kenji Sugiyama, Masahide Fujita, Yuko Iida, Hiroshi Nojima, Ikuo Saiki, Yasushi Kuraishi
• Journal: Biological & pharmaceutical bulletin (Biol Pharm Bull) Vol. 31 Issue 3 Pg. 520-2 (Mar 2008) ISSN: 0918-6158 [Print] Japan
• PMID: 18310922 (Publication Type: Journal Article)

Chemical References

• Analgesics, Non-Narcotic
• Analgesics, Opioid
• Morphine

Topics

• Administration, Oral
• Analgesics, Non-Narcotic (administration & dosage, pharmacology, therapeutic use)
• Analgesics, Opioid (administration & dosage, pharmacology, therapeutic use)
• Animals
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Drug Tolerance
• Hyperalgesia (drug therapy)
• Male
• Melanoma, Experimental (complications)
• Mice
• Mice, Inbred C57BL
• Morphine (administration & dosage, pharmacology, therapeutic use)
• Pain (drug therapy)
• Skin Neoplasms (complications)